Ginisortamab Reference: HY-P99643 Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors.
Nivatrotamab Reference: HY-P99757 Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.
Anti-Spike-RBD Single Domain mAb Reference: HY-P9802 Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity.
Samalizumab Reference: HY-P99400 Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.
Ontorpacept Reference: HY-P99777 Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
Baminercept Reference: HY-P99459 Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .
Tulinercept Reference: HY-P99543 Tulinercept (OPRX-106) is a monoclonal antibody. Tulinercept can be used for various biochemical studies.
Etesevimab Reference: HY-P99347 Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody.
Motavizumab Reference: HY-P99209 Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
Mirikizumab Reference: HY-P99737 Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody targets the p19 subunit of interleukin 23. Mirikizumab can be used for the research of ulcerative colitis.
Sugemalimab Reference: HY-P99114 Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
Emibetuzumab Reference: HY-P99192 Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.